CJC-1295 without DAC is a growth hormone–releasing hormone (GHRH) analog related to CJC-1295 but without the long-acting drug affinity complex (DAC) modification. It is commonly referenced as a shorter-acting GH-axis peptide in experimental and wellness contexts.

As with other GH-axis peptides, regulatory status and product quality controls vary, and many described uses lie outside established clinical guidelines.

CJC-1295 without DAC acts as a GHRH analog at the pituitary, stimulating growth hormone secretion in a more physiologic, pulsatile pattern than direct GH administration. Without the DAC modification, its duration of action is shorter than that of CJC-1295 with DAC.

The overall impact on GH/IGF-1 and downstream physiology depends on factors such as dose, timing, baseline GH-axis function, and co-administered agents.

CJC-1295 without DAC is not generally positioned as a first-line, labeled therapy for GH deficiency in contemporary guidelines. It appears mainly in experimental, wellness, or performance-related discussions.

For individuals evaluated for GH deficiency or related conditions, clinicians typically rely on established diagnostic protocols and therapies. Any use of CJC-1295 without DAC should be considered in light of local regulations and the availability of better-characterized options.

CJC-1295 is classified as a prohibited substance by WADA under category S2.

Notable athlete sanctions involving CJC-1295 include:

• Joey Coste (CrossFit): Received a 4-year sanction in 2022 for use of CJC-1295 and Ipamorelin.
• Ondrej Slezak (Cycling): Received a 4-year ban for multiple violations including CJC-1295 use.

Described effects include injection-site reactions, flushing, headache, and changes in sleep or energy patterns. Because the peptide influences GH/IGF-1, there are theoretical concerns about glucose metabolism and tissue growth over time.

As with any GH-axis intervention, clinician oversight and careful monitoring are important, especially in individuals with preexisting risk factors.

CJC-1295 without DAC (Mod GRF 1-29) has a short half-life (approx. 30 mins) intended to mimic natural physiological GHRH pulsatility. It is almost always paired with a GHRP (like Ipamorelin).

This information summarizes commonly discussed research practices and does not constitute medical advice.

In catalogs, CJC-1295 without DAC typically appears as a lyophilized powder for reconstitution and may be paired conceptually or in compounded products with GH secretagogues such as ipamorelin.

Structural listings on this site serve organizational purposes and do not recommend any specific combination or regimen.

Evidence for CJC-1295 without DAC includes limited studies on GH and IGF-1 responses, tolerability, and potential metabolic or body composition effects. The data set is smaller and more heterogeneous than that for established GH therapies.

As a result, claims about benefits should be balanced against uncertainties, and decisions should rely on comprehensive evaluation of risks, alternatives, and regulatory guidance.

Future FAQs might compare CJC-1295 without DAC conceptually with the DAC version and with other GH-axis agents, and outline the kinds of monitoring clinicians consider relevant when modulating GH physiology. Answers will remain educational and non-prescriptive.